This randomized prospective trial tested whether adding postoperative external-beam radiotherapy to limb-sparing surgery improves outcomes in extremity soft tissue sarcomas. It enrolled 141 patients across separate high-grade (with chemotherapy) and low-grade (surgery alone) cohorts, with a median follow-up approaching 10 years. The study measured local recurrence, overall survival, and prospective quality-of-life outcomes.
The question this trial answers is one every sarcoma surgeon still faces in clinic: does every patient need radiation after limb-sparing resection, or are we overtreating many patients?
XRT is highly effective at preventing local recurrence in both high-grade and low-grade extremity sarcomas. That benefit is real and statistically robust. But it never translates into living longer — overall survival is identical whether patients receive radiation or not.
This is why margin status drives the radiation decision. When a patient achieves a widely negative margin (>10 mm), zero patients in this trial recurred locally. For that patient, you are trading guaranteed joint stiffness, edema, and weeks of treatment for a recurrence that was never going to happen anyway.
The practical rule: reserve adjuvant XRT for patients with close or microscopically positive margins, recurrent tumors, or other high-risk features. In the low-risk, widely-excised patient, the functional cost of radiation outweighs the benefit — and this trial is the evidence behind that decision.
This randomized prospective trial tested whether adding postoperative external-beam radiotherapy to limb-sparing surgery improves outcomes in extremity soft tissue sarcomas. It enrolled 141 patients across separate high-grade (with chemotherapy) and low-grade (surgery alone) cohorts, with a median follow-up approaching 10 years. The study measured local recurrence, overall survival, and prospective quality-of-life outcomes.
The question this trial answers is one every sarcoma surgeon still faces in clinic: does every patient need radiation after limb-sparing resection, or are we overtreating many patients?
XRT is highly effective at preventing local recurrence in both high-grade and low-grade extremity sarcomas. That benefit is real and statistically robust. But it never translates into living longer — overall survival is identical whether patients receive radiation or not.
This is why margin status drives the radiation decision. When a patient achieves a widely negative margin (>10 mm), zero patients in this trial recurred locally. For that patient, you are trading guaranteed joint stiffness, edema, and weeks of treatment for a recurrence that was never going to happen anyway.
The practical rule: reserve adjuvant XRT for patients with close or microscopically positive margins, recurrent tumors, or other high-risk features. In the low-risk, widely-excised patient, the functional cost of radiation outweighs the benefit — and this trial is the evidence behind that decision.